Delivery Order SPE2DB22D2007-SPE2DB26FH6QD
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $3,562.33 to AmerisourceBergen Drug Corp for 1,000 tablets of Escitalopram 10 mg, with an ultimate completion date of August 25, 2025. This is a firm fixed-price delivery order with no set-aside designation, awarded competitively on August 22, 2025. The pharmaceutical product will be delivered to Conshohocken, Pennsylvania, where AmerisourceBergen Drug Corp maintains its corporate headquarters and primary operations. This delivery...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for 1,000 tablets of Escitalopram 10 mg, valued at $1,012.15, with an ultimate completion date of October 27, 2025. This competitively awarded contract utilizes firm fixed-price pricing with no set-aside designation and reflects the vendor's role as a critical pharmaceutical supplier to federal military and healthcare systems. The work will be performed at AmerisourceBergen's corporate office location in...
- The Defense Logistics Agency awarded a $2,395.86 delivery order to AmerisourceBergen Drug Corp on September 3, 2025, for the supply of 1,000 tablets of Escitalopram 10 mg. This is a firm fixed price, competitively awarded contract with no set-aside designation and an ultimate completion date of September 4, 2025. The pharmaceutical product will be delivered to Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. This delivery order is issued under...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Escitalopram 20 mg tablets (1,000 units) under a firm fixed-price contract valued at $1,740.43. The order was competitively awarded without set-aside designation and is scheduled for completion by September 10, 2025. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will fulfill this order from its corporate office location in the...
- The Defense Logistics Agency awarded a $1,711.70 delivery order to AmerisourceBergen Drug Corp on September 9, 2025, for the supply of 1,000 tablets of Escitalopram 10 mg, with completion scheduled for September 10, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 13, 2025, for the supply of 1,000 tablets of Escitalopram 10 mg, valued at $3,558.49 under a firm fixed-price contract. This delivery order represents a non-competitive, non-set-aside award issued under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.99 billion prime vendor agreement running through December 2026. The pharmaceutical product is...
- The Defense Logistics Agency awarded a $1,627.52 delivery order to AmerisourceBergen Drug Corp for 1,000 tablets of Escitalopram 10 mg, with performance scheduled for completion by September 3, 2025. This non-set-aside, competitively awarded contract employs firm fixed pricing and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a routine pharmaceutical procurement fulfilling federal medical supply requirements. This award...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on August 29, 2025, for the supply of Escitalopram 20 mg tablets in a quantity of 1,000 units, with a firm fixed price ceiling value of $4,295.66. The contract represents a non-set-aside, competitively awarded procurement with an ultimate completion date of September 2, 2025. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical...
- The Defense Logistics Agency awarded a $10,145.72 firm fixed-price delivery order to AmerisourceBergen Drug Corp on September 10, 2025, for the supply of 1,000 tablets of Escitalopram 20 mg, with an ultimate completion date of September 11, 2025. This non-set-aside contract will be performed at the contractor's Corporate Office location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and critical federal medical procurement vendor, is fulfilling...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on October 22, 2025, for the supply of 1,000 tablets of Escitalopram 20 mg, valued at $1,208.30. This competitively awarded, firm fixed-price delivery order is scheduled for completion by October 23, 2025, with performance taking place at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract carries no set-aside designation, reflecting open competition among qualified...
- SPE2DB22D2007Indefinite Delivery Contract
- SPE2DB22D2007-SPE2DB26FH6QDDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for 1,000 tablets of Escitalopram 10 mg under a firm fixed-price contract valued at $2,440.44. The order was competitively awarded without a set-aside designation and is scheduled for completion by October 30, 2025. AmerisourceBergen, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform the delivery from its corporate office location. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999.99 million through December 2026. This prime vendor contract serves as a comprehensive global pharmaceutical support vehicle enabling AmerisourceBergen to supply a broad range of medications, vaccines, and medical supplies to support military healthcare programs worldwide. The DLA Troop Support Medical Supply Chain relies on such vendor relationships to ensure consistent availability of critical pharmaceutical products, including both brand-name and generic medications, across multiple therapeutic domains for the Defense Health Agency, U.S. Coast Guard, and other federal healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $2.4k | 10/29/25 |